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INTRODUCTION
Diabetes Mellitus is a clinical syndrome characterized by hyperglycemia due to 
absolute or relative deficiency of insulin. Lack of insulin, whether absolute or relative 
affects the metabolism of carbohydrate, protein, fat(1) .
Pregnancy  is characterized  by  mild  fasting  hypoglycemia,  post-prandial 
hyperglycemia, hyperinsulinism and insulin resistance- a diabetogenic stress. Normally 
pregnant  woman  elaborates  an  increased  insulin  production  by  30% above  her  non 
pregnant state. A woman who is unable to achieve adequate insulinogenic compensation 
develops  Gestational  Diabetes.  Pregnancy  unmasks  the  minor  intolerance  of 
carbohydrate metabolism in subjects with reduced pancreatic islet cell reserve (2).
Gestational   Diabetes was defined as carbohydrate intolerance of variable severity 
with its onset or first recognition during pregnancy. Use of this term was encouraged in 
order to communicate the need for increased surveillance and to convince the woman of 
the need for further testing postpartum(3)
Gestational  Diabetes is  often asymptomatic and associated with increased fetal 
and  neonatal  morbidity  and  mortality.  Good  glycemic  control  reduces  the  risk  of 
complication(4).
CARBOHYDRATE METABOLISM IN NON DIABETIC PREGNANCY(5)
Factors contributing to insulin resistance
Production of placental somatomammotrophin, increased production of estrogen 
progesterone, increased insulin destruction by placental enzyme like insulinase.
Changes in Gluconeogenesis
Fetus continuously uses fuels from the mother. It uses alanine and other amino 
acids and depletes the mother of a major gluconeogenic source.
Increased Lipolysis
The mother uses fat for caloric needs and saves glucose for the fetus.
METABOLIC CHANGES DURING FASTING
During  fasting  there  is  decrease  in  plasma  and  amino  acids.  There  is  higher 
plasma concentration of free acids, triglycerides. During fasting for a longer period there 
is switch in metabolism from glucose to lipid which is termed “accelerated starvation” 
by Freinkel(8)
METABOLIC CHANGES DURING FED STATE(5)
During  the  first  few  hours,  glucose  absorbed  from the  gastro  intestinal  tract 
provides for the metabolic needs of brain and other organs. The absorbed glucose in 
excess of these needs is used to rebuild fuels in liver, muscle, fat and to provide supply 
of glucose for the fetus. This is facilitated anabolism.
REVIEW OF LITERATURE
HISTORY
Diabetes was described more than 2000 years ago. An ancient documentation by 
Susruta in India at about 400 B.C. has described the diabetic syndrome as characterized 
by  a  ‘honeyed  urine”.  The  word  Diabetes  (to  flow  through)  was  coined  by  Greek 
physician  Aretus Or Cappadocia  in first  century (150 A.D ) from the word siphon 
(sweet taste). The word mellitus (honeyed) was added by John Rollo in 18th century. 
In  1674,  Thomas Willis,  a  Physician,  Anatomist  and  a   professor  of  Natural 
philosophy  at  Oxford  discovered  by  tasting  that  the  urine  of  diabetic  persons  was 
“wonderfully sweet  as if  imbued with honey or sugar”.  Willis  could not explain the 
chemical nature of the sweet substance. It was Mathew Dobson of Manchester, England 
who in 1776 demonstrated that diabetics actually excrete sugar in urine. It was  John 
Rollo, surgeon general of Royal artillery who first applied the discovery of glycosuria 
by Dobson to the quantitative metabolic study of diabetes.
It  was  Claude  Bernard  who  studied  the  association  between  pancreas  and 
Diabetes.  The  name  Insulin  was  coined  by  De  Mayer  (1909).  In  1921  Fredrick 
Banting and Charles Best with the help of Chemist J.B.Collip succeeded in fulfilling 
all of the criteria for the therapeutic active Insulin.
Glucose  homeostasis  reflects  a  precise  balance  between  hepatic  glucose 
production and peripheral glucose uptake and utilization. Insulin is the mediator of most 
signals and hormones resulting in integrated control of glucose supply and utilization. In 
the fasting state low insulin levels increase glucose production by promoting hepatic 
gluconeogensis and glycogenolysis and reduce glucose uptake in insulin sensitive tissue. 
Glucagon also stimulates  glycogenolysis  and gluconeogenesis  by the liver  and renal 
medulla. Post prandially the glucose load elicits a rise in insulin and fall in glucagon. 
The major portion of post prandial glucose is utilized by skeletal muscles, an effect of 
insulin stimulated glucose uptake(6).
PATHOPHYSIOLOGY OF PERINATAL MORBIDITY
The  Pederson  hypothesis  suggested  that  in  diabetic  pregnancy  maternal 
hyperglycaemia  is  rapidly  translated  into  fetal  hyperglycaemia. The  fetal  pancreas 
responds to this glycaemic stimulatus with islet cell hypertrophy and hyperplasia and 
fetal  hyperinsulinism results.  It  is  the  fetal  hyperinsulinemia  that  results  in  diabetic 
fetopathy  or  prenatal  morbidity  seen  in  such  pregnancies.  According  to  modified 
Pederson hypothesis the non-glucose secretagogues for fetal pancreatic insulin also play 
a role in perinatal morbidity (25).
MODIFIED PEDERSEN / FRIENKEL’S HYPOTHESIS
The transport of maternal fuel to the fetus requires normal placental intermediary 
metabolism and normal supply of substrates. Because diabetes may result in markedly 
abnormal concentrations of maternal glucose, fatty acids, triglycerides and amino acids 
these may get transported to the fetus. Unlike the fetus of early gestation, the fetus of the 
late gestation is well equipped to synthesise and replace insulin from its pancreas and 
protect  itself  against  brunt  of  abnormal  brunt  of  abnormal  fuel  mixture,  thereby 
normalizing blood sugar in circulation but in the process resulting in hyperinsulinemia 
of  the  fetus  and  due  to  its  anabolic  action  causes  macrosomia  and  associated 
complications.
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Gestational  carbohydrate intolerance is asymptomatic.  The subjects destined to 
develop gestational diabetes mellitus have limited pancreatic insulin reserve and reduced 
insulin sensitivity. The stress of pregnancy due to counter insulin hormones overwhelms 
the insulin reserves. Hence in the plasma, levels of all classes of fuels - amino acids, 
fatty acids and glucose are elevated which are delivered to the fetus. This change is seen 
more  during  the  latter  half  of  pregnancy  when  counter  insulin  factors  and  insulin 
resistance  is  experienced.  The  fetal  transportation  of  abnormal  fuels  result  in 
hyperinsulinemia and during the delivery, RDS, neonatal hypoglycemia, hypocalcaemia, 
hyperbilirubinemia become the major concern for the subjects with gestational diabetes.
FREINKEL’S FUEL MEDIATED HYPOTHESIS:
    Pre-pregnancy
                                                                   
Congenital malformation
Behavioural changes
Anthropometric changes
  
      1st Trimester     2nd Trimester    3rd Trimester
Effects of abnormal glucose tolerance on the mother and the fetus: 
On the mother:
•Pre-eclampsia (16) is seen in 13.7% in Gestational Diabetes Mellitus, and 14.1% to 
27%   in  established  diabetes  mellitus.  Pre  -  eclampsia  and  pregnancy  induced 
hypertension  are  more  common  in  patients  with  Gestational  Diabetes  than  in 
controls(17). Combs et al Rosenn et al(18) reported a significant association between 
poor glycaemic control and pre - eclampsia  or pregnancy induced hypertension.
•The  incidence  of  chronic  hypertension(19)  is  2.5%  among  Gestational  Diabetes, 
against 0.3% in the non diabetic control group.
•Overall  incidence of ketoacidosis is 0.7% especially following beta agonist therapy. 
Kilvert  et  al.,  reported one case of  diabetic ketoacidosis in 150cases of  Gestational 
Diabetes Mellitus(20). Diabetic ketoacidosis is preventable and the prevention can be 
accomplished with optimal glycemic control.
•The  incidence  of  Hydramnios  ranges  from 2.0  to  2.1%(21)  in  gestational  diabetes 
mellitus and it is about 20% to 30% in overt diabetics. Most infants of hydramniotic 
diabetic  pregnancy  are  structurally  normal,  associated  with  increased  incidence  of 
preterm labour and premature rupture of membrane.
•Pyelonephritis was reported in 1.2% gestational diabetes mellitus and 3.6% of overt 
diabetes(19).  There is  no difference in the incidence of  pyelonephritis  in gestational 
diabetes mellitus and control groups.
•Preterm  labour  complicated  8.1  of  gestational  diabetes  mellitus  and  there  is  no 
significant difference in the preterm labour rate between gestational diabetes mellitus 
and control groups. There is significant  correlation between preterm labour and uro-
genital infection. (Candida and Trichomoniasis). Molsted and Pedersen (22) speculated 
that, hormonal differences increased the frequency of preterm labour in  a diabetic than 
in non-diabetic women.
•Spontaneous  pre-term  delivery  is  one  of  the  important  contributions  to  perinatal 
mortality  in  diabetic  pregnancies(22).  In  a  Scandinavian  report  by  Molsted  and 
Pederson,  the  incidence  of  preterm labour  with  delivery  was  14.6%  in  gestational 
diabetes mellitus versus 18 to 24% in established diabetes mellitus, and in the control 
group it was 12%.
•The incidence of primary caesarean section among gestational diabetes mellitus was 
16.5% and 6% among the control groups, There is a higher total caesarean section rate 
in gestational diabetes mellitus than controls(24).
Fetal Problems associated with maternal hyperglycemia
First Trimester Second Trimester Third Trimester
Malformations
Growth retardation
Hypertrophic cardiomyopathy
Polyhydramnios
Placental insufficiency
Pre-eclampsia
Fetal loss
Low IQ
Hypoglycemia
Hypocalcemia
Hyperbilirubinemia
Respiratory - distress 
Syndrome
Macrosomia
Hypomagnesemia
Intrauterine death
•Hypoglycemia is one of the common causes for perinatal morbidity. It is defined as 
blood sugar level less than 40mg% in any infant regardless of gestational age, About 
50%  of  the  hypoglycemic  babies  may  remain  asymptomatic.  The  factor  mainly 
protective against fetal hypoglycemia is the optimal control of maternal hyperglycemia 
especially during the third trimester and during labour. It had been shown that a mean 
maternal plasma glucose>105mg/dl during the last  four hours of labour in a diabetic 
mother leads to a higher incidence of neonatal hypoglycemia.
•About 25% of the infant of diabetic mothers may present with serum calcium of <7 mg/
dl and this may remain mostly asymptomatic and is usually detectable during the 2nd and 
3rd day of birth, Hypomagnesemia may coexist and may require correction.
•Respiratory  distress  syndrome (RDS)  occurs  in  about  5% of  the  infant  of  diabetic 
mothers and it is seen equally in gestational diabetes mellitus. Against a strict glycaemic 
control reduces the incidence of RDS.
•Polycythemia is relatively common in infant of diabetic mother. The hyperviscosity 
due  to  polycythemia  may  induce  congestive  heart  failure  and  vascular  thrombosis 
accounting for the increased risk of renal vein thrombosis in these infants.
•Hyperbilirubinemia, the common abnormality is due to increased bilirubin production 
and  decreased  life  span  of  the  RBCs  with  glycosylated  cell  membranes.  Hepatic 
conjugation of bilirubin may be impaired due to an immature liver. 
Gestational  Diabetes Mellitus   is  mostly  the forerunner  of  Type-2  Diabetes 
Mellitus(9). Like type-2 Diabetes mellitus, obesity and advanced maternal age increase 
the risk of gestational diabetes mellitus(10,11).
PREVALENCE
Ethnically Indian Women are more prone to develop glucose intolerance during 
pregnancy  and  have  eleven  fold  increased  risk  compared  to  white  Caucasian 
necessitating universal screening during pregnancy(7).
Prevalence of Gestational Diabetes is 2% to 5%  of all pregnancies in the United 
States(10). Marked variation has been reported in the prevalence of gestational diabetes 
world wide. The frequency of gestational diabetes mellitus ranged widely from 0.15% to 
as high as 50% in pima Indians in the USA (13).
MANAGEMENT 
           A very large number of these pregnant diabetics progress through pregnancy to 
manifest the consequences near or at term,when not much of effective intervention can 
be done. In those detected to have GDM and are not controlled with medical nutrition 
therapy,we  have  to  start  them  on  insulin,  a  potential  drug  with  its  attendant 
problems.Patient  compliance  is  a  problem  with  insulin  as  it  has  to  be  given 
subcutaneously and is painful. Not all patients are able to self administer the drug. In 
addition there are the complications such as hypoglycemia. 
          Pregnancy  in  individuals  with  diabetes  requires  meticulous  planning  and 
adherence to strict treatment regimes.Intensive diabetes management and normalisation 
of the HbA1c are the standard of care for pregnant diabetics. The most crucial period of 
glycemic control is soon after fertilisation. The risk of fetal malformations is increased 4 
to  10  times  in  individuals  with uncontrolled  diabetes  at  the  time of  conception  and 
normal plasma glucose during the preconceptional period and throughout the periods of 
organogenesis  should be maintained(6).  Fasting and post  prandial  blood glucose not 
more than 90 and 120 mg% are targeted. Optimum fetal outcome is with values around 
105mg%. Treatment options now used are
 medical nutrition therapy 
 insulin
 glyburide & metformin
Maintaining glucose levels within target range requires meticulous attention to 
diet and physical activity. For many patients, monitoring capillary glucose several times 
daily  and injecting  insulin  frequently  is  impossible.  For  this  reason,  there  are  many 
current initiatives to augment glucose control with oral agents, particularly in patients 
with insulin resistant type 2 diabetes. An ideal treatment would reduce insulin resistance, 
improve  insulin  secretion  or  action,  and delay  uptake  of  glucose  from gut.  Current 
strategies  are  aimed  at  augmentation  of  insulin  supply  [sulphonylureas  &  insulin 
therapy],  amelioration  of  insulin  resistance  [exercise,  weight  loss,  metformin  & 
troglitazone therapy], prevention of fetal complications [maintenance of euglycemia].
α-GLUCOSIDASE INHIBITORS
 Acarbose, voglibose
 Miglitol
Acarbose: 
Originally  developed  in  Germany,  is  a  pseudo-tetrasaccharide  derived  from  the 
fermentation process of the fungus Actinoplanes utahensis. It is a class of oral agents 
that  reversibly  inhibit  pancreatic  amylase  and  
α-glucosidase enzymes in the small intestines, delaying cleavage of complex sugars to 
monosaccarides and thus reducing the rise of blood glucose after a meal. Although these 
agents offer particular promise in pregnant women because of limited uptake from the 
gut,few studies in pregnancy are available to assess efficacy.  α-glycosidase inhibitors 
reduce postprandial hyperglycemia by delaying glucose absorption; they do not affect 
glucose  utilisation  or  insulin  secretion.  Postprandial  hyperglyceamia,  secondary  to 
impaired  hepatic  and  peripheral  glucose  disposal,  contributes  significantly  to  the 
hyperglycemic state in GDM. These drugs, taken just before each meal, reduces glucose 
absorption by inhibiting the enzyme that cleaves oligosaccharides into simple sugars in 
the intestinal lumen.
This  class  of  agents  is  not  as  potent  as  other  oral  agents  in  lowering  the 
hemoglobin A1c but it is unique  because it reduces the postprandial glucose rise even in 
individuals with type 1 DM. The average decrease in post prandial blood glucose during 
Acarbose treatment in diet treated type 2diabetic patients was 3mmol/l  and maximal 
decrease in HbA1c was 1%(29). If hypoglycemia occurs while taking these agents, the 
patient  should  consume  glucose  since  the  degradation  and  absorption  of  complex 
carbohydrates will be retarded.(6) Miglitol is absorbed systemically, hence not used in 
pregnancy.
Pharmacokinetics: 
Given orally less than 2% is absorbed as the oral drug. It is metabolized in the GI 
tract primarily by the intestinal bacteria and to a lesser degree by the digestive enzymes. 
Urine contains 2% of the drug and its metabolites. As a result, accumulation of the drug 
does not occur when given thrice daily.
Adverse effects:
Flatulence, soft stools, diarrhoea, abdominal distention and pain, rarely abnormal 
liver  function  tests  and  skin  reaction.  The  major  side  effects  (diarrhoea,  flatulence, 
abdominal distention) are related to increased delivery of oligosaccharides to the large 
bowel and can be reduced somewhat by gradual upward dose titration.
Contraindications:
Ulcerative colitis, partial intestinal obstruction, hepatic impairment, severe renal 
impairment, hernia, history of abdominal surgery. Simultaneous treatment with antacids 
is  to be avoided.  These agents should not  be used in individuals  with inflammatory 
bowel disease, gastroparesis, or serum creatinine >2.0mg/dl
Interactions:
Sucrose: Abdominal discomfort and diarrhoea.
Digestive  enzymes  [pancreatic  amylase]  and  intestinal  adsorbents:  reduce 
efficacy of Acarbose.
Sulphonyl ureas, biguanides: Acarbose increases their efficacy.
Insulin: In IDDM, insulin requirement is reduced.
Dosage:
Therapy should be initiated at a low dose [25mg] with the evening meal and may 
be increased to a maximal dose over weeks [50-100mg Acarbose or 50mg Miglitol with 
each meal].
IN PREGNANCY-Category B
These drugs act within the intestinal lumen and are not absorbed systemically. 
They thus have no adverse effect  on the developing fetus.  Few breakdown products 
which may enter the circulation do not have any known teratogenic effect. Reproduction 
studies has been done in rats at  doses upto 480mg/kg (corresponding to 9 times the 
exposure in humans,  based on drug blood levels)  and have revealed no evidence of 
impaired fertility or harm to the fetus due to Acarbose. In rabbits,  reduced maternal 
weight  gain,  probably  the  result  of  the  pharmacodynamic  effect  of  high  doses  of 
Acarbose in the intestines, may have been responsible for a slight increase in the number 
of embryonic losses. However, rabbits given 160mg/kg Acarbose (corresponding to 10 
times  the  dose  in  man,  based  on  body  surface  area)  showed  no  evidence  of 
embryotoxicity and there was no evidence of teratogenicity at a dose 32 times the dose 
in man.(27)
De Veciana et al, 2002 reported in abstract a randomized trial of acarbose versus 
insulin in 110 patents with GDM. Glycaemic control was considered equivalent in the 
2groups,  although  6%  of  the  acarbose  group  required  insulin  treatment  because  of 
gastrointestinal  side  effects.  No  significant  adverse  reactions  or  fetal  anomalies 
occurred. Acarbose is  given prior  to meals,  initially 25mg orally 3 times daily, to a 
maximum of 100mg orally 3 times daily. Both groups improved their glucose levels 
with treatment.  There was no differences between groups in maternal  demographics, 
duration of therapy, glucose levels, birth weight, gestational age, or ceasarian section 
rate, she said (28).
Acarbose is classified by the Food and Drug Administration in pregnancy risk 
category B, meaning there is no evidence that it poses a risk to human fetuses.
AIMS AND OBJECTIVES
1To study Acarbose as a new line of management in GDM.
2Study its  efficacy in glycaemic control,  prevention of  maternal  complications & 
fetal outcome.
MATERIALS AND METHODS
1. Study design : Prospective study.
2. Study place : Institute of Obstetrics & 
Gynaecology, Chennai.
3. Study population : Pregnant GDM between 16-32 
weeks gestation.
4. Sample size : 30
5. Year of study : January 2007-  July 2008
INCLUSION CRITERIA
1. GDM with 75g GTT >140mg % at 2 hours.
2. Patients whose blood sugar was not controlled with medical nutrition therapy, i.e: 
FBS>95mg/dl or PPBS>120mg/dl.
3. 16-32 weeks of gestation.
EXCLUSION CRITERIA
1< 16 wk, > 32 weeks gestation.
2Known Diabetic.
3If blood sugar is controlled with medical nutrition therapy. i.e; FBS<95mg/dl or 
PPBS<120mg/dl.
4Multiple pregnancy.
5Anomalous fetus.
METHOD OF THE STUDY
Pregnant women of gestational  age between 16 to 32 weeks attending the out 
patient  department  for  their  antenatal  check  up were  subjected  to  the  WHO 75 gm 
glucose  challenge  test.  Known diabetics  were excluded.  All  those  who had a  blood 
glucose value  > 140mg/dl at 2 hours were started on medical nutrition therapy for 2 
weeks. 
After 2 weeks, patients were instructed to come in an over night fasting state of 8 
hours. A 2 hour glucose tolerance test was done and only those patients who had a 
fasting blood glucose >95mg/dl and/or 2 hour post prandial blood glucose >120mg/dl 
were included in the study after obtaining an informed consent.
All patients included in the study were started on Acarbose, the minimum dose 
being 25 mg BD. At the outset baseline liver function test, lipid profile and maternal 
HbA1c was obtained. After starting the patient on Acarbose they were reviewed every 
15  days  with  fasting  and  postprandial  blood  sugar  measurement  alternating  with 
glycemic profile every fortnight. The drug dose was titrated depending on the response 
and blood glucose levels to achieve optimum control. The aim was to have a mean blood 
glucose of 105 mg/dl. If blood sugar was not controlled with Acarbose they would be 
switched over to insulin therapy. Ultrasound for anomalies, to monitor growth, detect 
any deviation from the normal growth curve, amount of liquor and for fetal well being 
was done at 20-22 weeks, 28 weeks,32 weeks and at 36 weeks. The patients were thus 
followed until delivery. Immediately after delivery the maternal blood sugar and HbA1c 
was measured to assess the glycaemic control that was achieved with the drug. The cord 
blood insulin levels were also measured to look for  hyperinsulinism in the newborn 
baby. Perinatal outcome was recorded. All blood sugar measurements were done using 
the Enzymatic method in our hospital.
RESULTS AND ANALYSIS
TABLE - 1
AGE
AGE FREQUENCY PERCENTAGE
20-25 yr
26-30 yr
31-35 yr
36-40 yr 
14
12
3
1
46.7
86.7
10.0
3.3
Total 30 100
One-Sample Statistics
30 26.5667 4.35243 .79464AGE
N Mean Std. Deviation
Std. Error
Mean
The mean age of GDM patients was 26.5667 years and majority of the cases were 
in the <25 years group
Table - 2
Gestational Age
One-Sample Statistics
30 162.2000 22.76931 4.15709
30 144.7050 24.87467 4.54147
30 3.0667 2.51798 .45972
SCREENING   GCT
INCLUSION GTT
INCLUSION GTT GROUP
N Mean Std. Deviation
Std. Error
Mean
The mean Gestational age at Screening is 26.00 weeks ,at Inclusion is 27.933 and 
at Delivery is 38.433.
Table - 3
Obstetric history
GRAVIDITY FREQUENCY PERCENTAGE
Primi 9 30.0
Gravida2 15 50.0
Gravida3 5 16.7
Gravida4 1 3.3
30% of the GDM cases were Primis and the incidence of GDM was more in multi 
gravida than in Primis.
Table - 4
Family history
FAMILY HISTORY FREQUENCY PERCENTAGE
Present 22 73.3
Absent 8 26.7
Total 30 100
73.3% of  the cases of GDM had a positive family history of Diabetes.
Table - 5
BMI group
BMI CATEGORY FREQUENCY PERCENTAGE
<18.5 8 26.7
18.5-24.9 18 60.0
25-29.9 3 10.0
>30 1 3.3
Total 30 100
Majority of the cases of GDM(60%) fell in the normal BMI group, though  7 of 
them(26.7%) had BMI less than normal.
One-Sample Statistics
30 21.8117 3.60667 .65849BMI
N Mean Std. Deviation
Std. Error
Mean
The mean BMI value among the GDM cases was21.8117 which fell in the normal 
BMI range.
BMI  GROUP * MAXIMUM  DOSE GROUP Crosstabulation
3 1 2 2 0 0 0 8
37.5% 20.0% 40.0% 28.6% .0% .0% .0% 26.7%
10.0% 3.3% 6.7% 6.7% .0% .0% .0% 26.7%
4 3 3 4 1 0 3 18
50.0% 60.0% 60.0% 57.1% 100.0% .0% 100.0% 60.0%
13.3% 10.0% 10.0% 13.3% 3.3% .0% 10.0% 60.0%
0 1 0 1 0 1 0 3
.0% 20.0% .0% 14.3% .0% 100.0% .0% 10.0%
.0% 3.3% .0% 3.3% .0% 3.3% .0% 10.0%
1 0 0 0 0 0 0 1
12.5% .0% .0% .0% .0% .0% .0% 3.3%
3.3% .0% .0% .0% .0% .0% .0% 3.3%
8 5 5 7 1 1 3 30
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
26.7% 16.7% 16.7% 23.3% 3.3% 3.3% 10.0% 100.0%
Count
% within MAXIMUM
DOSE GROUP
% of Total
Count
% within MAXIMUM
DOSE GROUP
% of Total
Count
% within MAXIMUM
DOSE GROUP
% of Total
Count
% within MAXIMUM
DOSE GROUP
% of Total
Count
% within MAXIMUM
DOSE GROUP
% of Total
1.00
2.00
3.00
4.00
BMI 
GROUP
Total
1.00 2.00 3.00 4.00 6.00 7.00 8.00
MAXIMUM  DOSE GROUP
Total
Chi-Square Tests
17.100a 18 .516
14.954 18 .665
.468 1 .494
30
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
28 cells (100.0%) have expected count less than 5. The
minimum expected count is .03.
a. 
The BMI did not correlate with the titration of drug dosage, they were found to be 
independent of each other.(p>0.05 not significant).
Table - 6
Delivery mode
FREQUENCY PERCENTAGE
Labour natural 12 40.0
LSCS 5 16.7
Total 17 56.7
17 patients had previous pregnancies carried to term, 12 (70.6%)had a normal 
delivery while 5(29.4%) of them had a Caesarean section.
Table - 7
Indication for Caesarean section:
INDICATION FREQUENCY PERCENTAGE
Fetal distress 2 6.7
PROM with failed acceleration 1 3.3
CPD 1 3.3
Placenta preavia 1 3.3
Table - 8
Maternal complications
Past pregnancy Present pregnancy
PIH 3 5
PCOS 1 2
IGT 1 0
In the preceding pregnancy the most common maternal complication was PIH, 
which is a risk factor in the present pregnancy too.
Table - 9
Fetal wastage in previous pregnancies:
NUMBER OF 
ABORTIONS
FREQUENCY PERCENTAGE
1 7 23.3
2 1 3.3
In the study group 8 patients had previous early pregnancy losses,1 of whom had 
2 previous abortions.
Neonatal complications in previous pregnancies:
COMPLICATION FREQUENCY PERCENT
IUD 1 3.3
Neonatal jaundice 1 3.3
In the study group 1 baby died in the perinatal period of Jaundice and one patient 
had an intra uterine fetal demise.
Table - 10
Glycaemic control:
Blood sugar at screening:
BLOOD SUGAR(mg%) FREQUENCY PERCENTAGE
140-149 11 36.3
150-159 6 20
160-169 7 23.3
170-179 2 6.7
180-189 0 0
190-199 1 3.3
200-209 0 0
210-219 2 6.7
220-229 0 0
230-239 1 3.3
Table - 11
Mean Blood sugar at inclusion
BLOOD SUGAR 
(mg %)
FREQUENCY PERCENTAGE
120-129 6 20
130-139 10 33.3
140-149 8 26.7
150-159 2 6.7
160-169 0 0
170-179 2 6.7
180-189 0 0
190-199 0 0
200-209 0 0
210-219 1 3.3
220-229 0 0
230-239 1 3.3
One-Sample Statistics
30 162.2000 22.76931 4.15709
30 144.7050 24.87467 4.54147
30 3.0667 2.51798 .45972
SCREENING   GCT
INCLUSION GTT
INCLUSION GTT GROUP
N Mean Std. Deviation
Std. Error
Mean
The mean Blood sugar at screening is162.20 and at inclusion is 144.7050,which 
reflects that the blood sugar is uncontrolled even after medical nutrition therapy.
Table - 12
DRUG DOSAGE
DRUG DOSE(mg) FREQUENCY PERCENTAGE
75 8 26.7
100 5 16.7
125 5 16.7
150 6 20.0
175 1 3.3
200 1 3.3
225 1 3.3
250 3 10.0
Total 30 100.0
The mean dosage of the drug used was 131.6667mg with S.D.55.29441. 26.7% of 
the patients required a maximum of 75mg only, the next largest group23.3% requiring 
150 mg. The maximum dose used was 250 mg which was used in 10% of the cases.
PRESENT BIRTH WEIGHT Vs MAXIMUM DOSE Cross tabulation
PRESENT BIRTH WEIGHT GROUP * MAXIMUM  DOSE GROUP Crosstabulation
1 0 0 0 0 1 0 2
3.3% .0% .0% .0% .0% 3.3% .0% 6.7%
1 0 1 0 0 0 1 3
3.3% .0% 3.3% .0% .0% .0% 3.3% 10.0%
3 1 1 3 0 0 0 8
10.0% 3.3% 3.3% 10.0% .0% .0% .0% 26.7%
2 2 1 3 0 0 1 9
6.7% 6.7% 3.3% 10.0% .0% .0% 3.3% 30.0%
1 0 1 0 0 0 1 3
3.3% .0% 3.3% .0% .0% .0% 3.3% 10.0%
0 1 1 0 0 0 0 2
.0% 3.3% 3.3% .0% .0% .0% .0% 6.7%
0 1 0 0 1 0 0 2
.0% 3.3% .0% .0% 3.3% .0% .0% 6.7%
0 0 0 1 0 0 0 1
.0% .0% .0% 3.3% .0% .0% .0% 3.3%
8 5 5 7 1 1 3 30
26.7% 16.7% 16.7% 23.3% 3.3% 3.3% 10.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Count
% of Total
Count
% of Total
Count
% of Total
Count
% of Total
Count
% of Total
Count
% of Total
1.00
2.00
3.00
4.00
5.00
6.00
7.00
9.00
PRESENT
BIRTH
WEIGHT
GROUP
Total
1.00 2.00 3.00 4.00 6.00 7.00 8.00
MAXIMUM  DOSE GROUP
Total
One baby (3.3%) had a birth weight >4kg (macrosomia) but the maternal blood 
sugar  was  controlled with 150 mg of  Acarbose.30% of the babies born had a  birth 
weight ranging between 2.76-3.00 and 26.7% had birth weight between 2.51-2.75 all of 
whose maternal blood sugar was controlled with drug dosage not exceeding150 mg.
Table - 13
HbA1c-at inclusion and delivery
HbA1c (%) AT INCLUSION AT DELIVERY
4.5-5.0 0 1
5.0-5.5 1 2
5.5-6.0 6 18
6.0-6.5 7 7
6.5-7.0 13 1
7.0-7.5 2 0
7.5-8.0 1 1
A. AT INCLUSION One-Sample Statistics
30 6.4900 .54034 .09865INCLUSION Hb1ac
N Mean Std. Deviation
Std. Error
Mean
 HbA1c  values  at  inclusion  into  the  study  had  a  mean  value  6.49%  and 
S.D.0.54034
B. AT DELIVERY One-Sample Statistics
30 5.9767 .46660 .08519MOTHER Hba1c
N Mean Std. Deviation
Std. Error
Mean
HbA1c values at delivery, after treatment with Acarbose had a mean value of 
5.9767% and S.D.0.46660
HbA1c at Delivery
HbA1c (%) FREQUENCY PERCENTAGE
4.5-5.0 1 3.3
5.0-5.5 2 6.7
5.5-6.0 18 60.0
6.0-6.5 7 23.3
6.5-7.0 1 3.3
7.0-7.5 0 0
7.5-8.0 1 3.3
At the time of delivery 60% of case had HbA1c between 5.5-6.0% and 23.3% 
between 6.0-6.5. Only 1 case (3.3%) had HbA1c >7.5%.
Table - 14
INCLUSION vs. DELIVERY HbA1c
Paired Samples Statistics
6.4900 30 .54034 .09865
5.9767 30 .46660 .08519
INCLUSION Hb1ac
MOTHER Hba1c
Pair
1
Mean N Std. Deviation
Std. Error
Mean
Paired Differences
Mean Std. Deviation Std. Error Mean Sig. (2 - tailed)
Inclusion HbA1c and 
Delivery HbA1c
.5133 .38303 .6993 .000
Comparing the maternal  HbA1c at inclusion into the study and at the time of 
delivery has p=0.000 which is highly significant (Mc Nemar test)
Table - 15
MEAN GLYCEAMIC CONTROL:
Mean Blood Sugar
Descriptives
MEAN BS
24 103.8021 6.76138 1.38016 100.9470 106.6572 93.86 119.16
1 115.3700 . . . . 115.37 115.37
3 113.9067 6.94713 4.01093 96.6490 131.1643 105.92 118.55
1 103.0600 . . . . 103.06 103.06
1 105.2100 . . . . 105.21 105.21
30 105.2203 7.26426 1.32627 102.5078 107.9329 93.86 119.16
.00
1.00
2.00
4.00
5.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
   The mean Blood sugar achieved during the antenatal period by titrating the drug dose 
is 105.2203mg/dl with S.D.7.26426
Inclusion GTT blood sugar Vs. Mean Blood sugar  during Pregnancy:Paired Samples Statistics
144.7050 30 24.87467 4.54147
105.2203 30 7.26426 1.32627
INCLUSION GTT
MEAN BS
Pair
1
Mean N Std. Deviation
Std. Error
Mean
Paired Samples Test
39.4847 23.35831 4.26463 30.7625 48.2068 9.259 29 .000
INCLUSION
GTT - MEAN BS
Pair
1
Mean Std. Deviation
Std. Error
Mean Lower Upper
95% Confidence
Interval of the
Difference
Paired Differences
t df Sig. (2-tailed)
Significance  (2-tailed)  -  .000.  The  mean  blood  sugar  at  inclusion  is 
144.7050mg/dl  and during the antenatal  period is 105.2203. The calculated value of 
p=0.000 which is highly significant.
Table - 16
Neonatal blood sugar:
BLOOD SUGAR 
(mg%)
FREQUENCY PERCENTAGE
51-55 2 6.7
55-60 5 16.7
60-65 6 20.0
65-70 6 20.0
70-75 4 13.3
75-80 5 16.7
80-85 1 3.3
85-90 1 3.3
Total 30 100.0
Major proportion(40%) of the babies had blood sugar in the range of 61-70 mg/dl 
and only 2 (6.7%)babies with blood sugar between 51-55mg/dl.
One-Sample Statistics
30 3.9667 1.79046 .32689BABY  BS  GROUP
N Mean Std. Deviation
Std. Error
Mean
The mean Neonatal blood sugar was 68.062435 mg/dl.
Table - 17
Birth weight
BIRTH WEIGHT (KG) FREQUENCY PERCENTAGE
2.0-2.25 2 6.7
2.25-2.5 3 10.0
2.5-2.75 8 26.7
2.75-3.0 9 30.0
3.0-3.25 3 10.0
3.25-3.5 2 6.7
3.5-3.75 2 6.7
3.75-4.0 0 0
4.0-4.25 1 3.3
One-Sample Statistics
30 2.9000 .44856 .08190
PRESENT 
BIRTH WEIGHT
N Mean Std. Deviation
Std. Error
Mean
The mean Birth weight of the babies born was 2.900 kg with S.D. 0.44856.
Paired Samples Statistics
2.6000 17 .60699 .14722
2.9088 17 .50782 .12317
PRE. BIRTH WEIGHT
PRESENT  BIRTH
WEIGHT
Pair
1
Mean N Std. Deviation
Std. Error
Mean
Paired Samples Test
-.3088 .50132 .12159 -.5666 -.0511 -2.540 16 .022
PRE. BIRTH WEIGHT
- PRESENT  BIRTH
WEIGHT
Pair
1
Mean Std. Deviation
Std. Error
Mean Lower Upper
95% Confidence
Interval of the
Difference
Paired Differences
t df Sig. (2-tailed)
The mean Birth weight of babies born in previous pregnancies (before treatment) 
was 2.600kg and in the present pregnancy is 2.9088kg. P=0.022 Significant.
Table - 18
Cord blood insulin
CORD BLOOD 
INSULIN(μg%)
FREQUENCY PERCENTAGE
5.6-6.0 3 10.0
6.1-6.5 12 40.0
6.6-7.0 8 26.7
7.1-7.5 6 20.0
7.6-8.0 1 3.3
40% of the study group had Cord blood insulin of 6.1-6.5µg/dl and in 3.3% it was 
7.6-8.0µg/dl
One-Sample Statistics
30 6.6033 .52751 .09631 CORD BLOOD INSULIN
N Mean Std. Deviation
Std. Error
Mean
Mean cord blood insulin of the babies delivered was 6.6033 µg/dlwith S.D.0.52751.
TABLE - 19
Ultrasound monitoring
USG at 22 weeks-1 case of Anomaly
USG at 28 weeks
USG FINDING FREQUENCY PERCENT
1.Macrosomia 1 3.3
2.Hydramnios 1 3.3
USG at 28 week revealed 1 case with Macrosomia and 1 case with Hydramnios.
USG at 32 weeks
USG FINDING FREQUENCY PERCENTAGE
1.Macrosomia 1 3.3
2.Hydramnios 1 3.3
3.Oligohydramnios 1 3.3
USG at 32 weeks revealed 1 case of Macrosomia, Hydramnios and IUGR each.
USG at 36 weeks
USG FINDING FREQUENCY PERCENT
1.Macrosomia 1 3.3
2.Hydramnios 3 10.0
3.Oligohydramnios 1 3.3
4.IUGR 1 3.3
USG at 36 weeks revealed 1 case of Macrosomia, 3 cases of Hydramnios, 2 cases 
of Oligohydramnios and 1 case of IUGR.
Table - 20
PRESENT DELIVERY
Delivery mode
MODE OF DELIVERY FREQUENCY PERCENTAGE
Labour natural 20 33.3
LSCS 10 66.7
Total 30 100
66.7% of the cases delivered normally and 33.3% were delivered by LSCS.
LIVE BABY
30 100.0 100.0 100.01.00Valid
Frequency Percent Valid Percent
Cumulative
Percent
100% of the patients delivered a live viable baby.
SEX:
SEX FREQUENCY PERCENTAGE
Male 15 50.0
Female 15 50.0
The babies delivered were 50% male and 50% female.
TABLE -21
APGAR
APGAR FREQUENCY PERCENTAGE
>7 29 96.7
<7 1 3.3
 96.7% of the babies had a good Apgar score and 3.3% had an Apgar <7.
TABLE - 21
MATERNAL DELIVERY BLOOD SUGAR:
Inclusion GTT Vs Blood Sugar at Delivery
Paired Samples Statistics
144.7050 30 24.87467 4.54147
84.8667 30 9.89857 1.80722
INCLUSION GTT
BS DEL
Pair
1
Mean N Std. Deviation
Std. Error
Mean
The  mean  Blood  sugar  at  inclusion  was  144.7050mg/dl  and  at  delivery  was 
84.8667mg/dl.
Paired Samples Test
59.8383 25.34000 4.62643 50.3762 69.3004 12.934 29 .000
INCLUSION
GTT - BS DEL
Pair
1
Mean Std. Deviation
Std. Error
Mean Lower Upper
95% Confidence
Interval of the
Difference
Paired Differences
t df Sig. (2-tailed)
 P=0.000 which is highly significant.                             
DISCUSSION
A prospective study was conducted in IOG during Jan 2007-July 2008. For this 
study 1000 randomly selected pregnant women in 16-32 weeks gestation were screened 
and 30 cases of GDM were diagnosed based on WHO-GCT. They were included in the 
study.
PREVALENCE:
 According  to  Beischer  et  al,  1991,  the  prevalence  of  GDM  in  the  Indian 
subcontinent is 15%.
In  a  study  conducted  in  Jean  Verdier  Hospital,  France  it  was  identified  that 
prevalence of GDM was 15.65%, if universal screening is adopted. 
In a study conducted by  Dr.Anjalakshi  for evaluation of diagnostic criteria for 
AGT in south Indian pregnant women, prevalence of GDM was found to be 15%.
Seshiah et al found the prevalence to be 16.2% in India in his study using WHO 
criteria.
Schmidt et al in 2001 found the incidence to be 7.2% by WHO criteria.
In our study the prevalence of GDM by WHO criteria was 3% since we were 
taking  only  women  16-32  weeks  of  gestation  and  excluding  diabetics,  multiple 
pregnancies and anomalous fetuses
AGE:
Coustan found that the incidence of GDM is 3.8% in women of 30-34 years of 
age but  only 0.7% in women younger than 21 years in a larger  study of unselected 
population.
Seshiah et al in his study in 2005 found that the incidence of DM in <20 years is 
14.5%,20-24 years is 13.7%,25-29 years is 19.5%, >30 years is 25%.
In our study the mean age of the GDM patients was 26.5667 years.
GESTATIONAL AGE:
A study was done by Seshiah et al for detection of GDM in the three trimesters of 
pregnancy. Among the studied patients 16.3% were within 16 weeks of gestation, 23.1% 
were between 17-23 weeks of gestation,60.6% were more than 24 weeks .
In our study, the mean gestational age at screening was 26 weeks and at delivery 
was 38.433 weeks.
OBSTETRIC HISTORY:
Prevalence of gestational diabetes increases with gravidity from 16-3% in primis 
to 25-8% in gravida > 4 in a study by Seshiah et al.
Pyke De et al found that the incidence of GDM increases with parity.
In our study, 30% of the DM cases were primis and the incidence of GDM was 
more in multi gravida than primis.
FAMILY HISTORY:
Serirat et al  in 1992 have shown that family history of diabetes is present in 
23.1% of patients with abnormal glucose tolerance.
Moses et  al  has shown that  family history of diabetes is  present  in 11.6% of 
patients with GDM.
In our  study,  positive  family  history  was  present  in  73.3% of  cases  of  GDM 
(p=0.0).
BMI:
Serirat  et  al  in  1992,  in  a study found that  obesity  was present  in  26.5% of 
patients with GDM.
In a study by  Seshiah et al  the incidence of GDM was 33.3% in patients with 
BMI > 30. 
In our study 60% of cases of GDM fell in the normal BMI group, 26.7% had less 
than normal BMI and 3.3% had BMI  > 30. This shows that  the incidence of GDM 
among the patients with low BMI should not be overlooked. In this study,  the drug 
dosage required to achieve glycemic control did not correlate with the BMI (p=0.516).
PREVIOUS DELIVERY:
17 cases had previous deliveries of which 70.6% was normal delivery and 29.4% 
had  Caesarean  section.  In  the  study  66.7%  had  normal  delivery  and  33.3%  had 
Caesarean section. The difference between the previous delivery when they did not have 
GDM and now when they do is not significant. there were no difficult deliveries either.
MATERNAL COMPLICATIONS
Maternal  mortality  has become rare in women with diabetes  a emphasized by 
Cousins  who  stated  that  mortality  is  increased  10  fold,  most  often  as  a  result  if 
ketoacidosis,  hypertension,  preeclampsia,  pyelonephritis  and  patients  with  coronary 
artery disease. In our study there was no morality.
Suhoven  and  Terano  et  al  in  1993  reported  the  incidence  of  PIH  and 
preeclampsia to be 2 times more common among GDM patients than controls (19.8% 
vs. 10%).
In a study Schmidt et al, it was found that frequency of preeclampsia was 5%.
PIH was seen in 13.7% in GDM in a study by Cousins et al.
In our study, PIH in the preceding pregnancy was the most common risk factor 
and in the present pregnancy complicated by GDM, the incidence of PIH is shown to be 
more.
FETAL WASTAGE:
Zarate et al in 2000, did a study in 6 pregnant women who were treated with 
Acarbose. All pregnancies were uneventful and the newborns were considered normal.
Sherry Boschert in Aug,2002 compared insulin therapy to Acarbose treatment in 
GDM. She found no significant difference between the two groups in fetal outcome.
In the study group 8 patients had previous early pregnancy losses,1 of whom had 
2 previous abortions,1 patient  had an IUFD and 1 patient  lost  the previous baby to 
perinatal jaundice. Thus the incidence of fetal wastage was 33.3%. After treatment with 
Acarbose all the present pregnancies were carried to term with no fetal wastage.96.7% 
of the babies had a good Apgar score of >7.
FETAL COMPLICATIONS:
Bertini et al, J.Perinatal medicine, 2005 studied the perinatal outcome in GDM 
cases managed with insulin, glyburide and Acarbose. The rate of large for gestational 
age fetuses in each group was 3.7%, 25% and 10.5% respectively.
At term, in our study, there was 1 case of macrosomia-3.3% (with onset before the 
start  of  treatment  with  Acarbose),  3  cases  of  hydramnios  10%,  2  cases  of 
oligohydramnios  and  1  case  of  IUGR  which  was  most  probably  due  to  the 
accompanying PIH in that mother.
GLYCAEMIC CONTROL:
In studies conducted  Margarita deVeciana, ACOG  showed glycaemic control 
similar to insulin was achieved, with only 5% who had to be switched over to insulin 
due to GI side effects.
Bertini  AM  et  al  found  that  glucose  control  was  not  achieved  in  42.1% of 
patients using Acarbose.
In our study, Patients were started on Acarbose and the glycaemic control was 
good  with  the  mean  blood  sugar  being  105.3303mg/dl.
(p-0.00). No patient had hyperglyceamia which required change of treatment.
At the time of delivery the mean blood sugar was 84.8667mg/dl indicating good 
control of blood sugar is achieved using Acarbose alone (p=0.00).
DRUG DOSAGE:
Margarita de Veciana in her study with 56 patients in the Acarbose group started 
out taking 25mg of the agent thrice daily with the first bite of each meal. The dose was 
increased as needed to a maximum of 100mg TDS. At term, the mean total daily dosage 
was 120mg/day in the Acarbose group.
This  is  comparable  to  our  study  where  the  mean  total  daily  dose  was 
131.667mg/day. The maximum dose used in our study was 250mg in 10% of the cases, 
while most cases achieved glycemic control with 75mg (26.7%) and 150mg (23.3%).
HbA1c:
De Veciana et al in their study showed that the HbA1c reduction with Acarbose 
was comparable to insulin.
VS Reddy, RK Sahay et al in their paper on newer oral ant diabetic agents said 
the maximal decrease in HbA1c that could be achieved with Acarbose was 1%.
In our study the mean HbA1c when the patients were diagnosed to have GDM 
was 6.49%. After treatment with Acarbose the mean HbA1c at delivery was 5.9767% 
(p=0.00) showing a reduction of 0.52%.
NEONATAL BLOOD SUGAR:
Cowett  et  al  found  that  infants  of  women  with  GDM have  an  incidence  of 
neonatal hypoglycemia that approaches 30-50%.
According to James the frequency of hypoglycemia is 18-49%.
The mean neonatal blood sugar was 68.06mg/dl with 40% of babies having blood 
sugar 61-70mg/dl and only 6.7% with blood sugar between 51-55mg/dl in our study. 
There were no cases of hypoglycemia, indicating there was no hyperinsulinemia in the 
babies causing this complication.
BIRTH WEIGHT:
Spellacy, WN Miller, S Winegar found that Macrosomia was present in 50% of 
pregnancies with GDM.
Langer  et  al  also  found  50%  of  pregnant  patients  with  GDM  to  have 
Macrosomia.
In  our  study  the  mean  birth  weight  was  2.9  kg  with  1  case  of  macrosomia 
comparing  with  previous  pregnancy  birth  weight  of  2.6kg,  there  is  a  significant 
difference. But there was no resulting complications due to the increase in birth weight.
CORD BLOOD INSULIN:
In our study, the mean cord blood insulin was 6.6033µg/dl with 40% having cord 
blood insulin of 6.1-6.5µg/dl.
SUMMARY
1.In the patients recruited into the study, the mean age was 26.5667 years.
2.73.3% of GDM cases had a positive family history.
3.60% of GDM cases had a normal BMI.BMI did not correlate with titration of drug 
dosage which has to be individualized.
4.The  maternal  complications  encountered  in  the  study  was  PIH  and  PCOS  ,the 
incidence of which was the same as non-GDM cases.
5.The fetal wastage in the previous pregnancies was 47.62% when the patients were not 
diagnosed or treated for GDM. In the study fetal complications were only 3.33%(1 case 
of  respiratory  distress)  after  treatment  with  Acarbose.  Macrosomia  and  fetal 
hyperinsulinism were prevented by Acarbose.1 case of macrosomia had onset before 
Acarbose was started and hence was excluded from our statistics.
6.Mean drug dose needed for  glycemic  control  was 131.6667mg with most  patients 
requiring 75 -150mg of Acarbose. But the dosage has to be individually titrated for each 
patient.
7.Maternal HbA1c and maternal blood sugar was statistically reduced after treatment 
with Acarbose.
8.Glycemic  control  was  good  and  the  aimed  level  of  105mg%  was  achieved  with 
Acarbose treatment.
9.The  mean  neonatal  blood  sugar  was  68.062435mg/dl  with  no  baby  going  for 
hypoglycemia.
10. In  the present  pregnancy,  all  pregnancies were safely  carried to  term,  66.7% of 
patients delivered normally, with 96.7% of babies having a good Apgar score.
                           
CONCLUSION
GDM  patients  treated  with  Acarbose  had  good  glycemic  control  during  the 
antenatal  period  and  delivery.  It  prevented  the  maternal  complications  due  to 
hyperglycemia,  as  well  as  complications  for  the  fetus  like  macrosomia,  anomalies, 
growth  restriction,  hyperinsulinism,  hypoglycemia,  etc.  The  fetal  outcome  after 
treatment of GDM with Acarbose was good. There were no adverse effects of the drug. 
It obviated the need for use of insulin. 
    Thus  Acarbose  is  a  safe  and  effective   oral  drug  in  the  management  of  GDM 
achieving good glycaemic control and preventing maternal and fetal complications of 
GDM.
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PROFORMA:
A. GENERAL:
Name:                         Age:                 Education:
Address & telephone no:
Date of inclusion into study:
B. OBSTETRIC HISTORY:
LMP:               EDD: 
Gestational age at time of inclusion into study:
Gravida Para Abortion Stillbirth
C.FAMILY HISTORY:
Father:                                1st degree relatives:
Mother:                               Siblings:
D.GENERAL EXAMINATION:
Anemia:
Pedal edema:
Acanthosis nigricans:
B.P.
Ht:               Wt:
Prepregnancy Wt:
BMI(calculated from prepregnancy wt.):
E. ASSOCIATED PROBLEMS IN PREVIOUS PREGNANCY:
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F. PREVIOUS PRENANCY OUTCOME:
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G. SCREENING DETAILS:
Date of screening :
Week of gestation :
FPG :
2 hour PPG :
H. OTHER INVESTIGATIONS:
Microalbuminuria :
Retinopathy :
Others: : 
I. TREATMENT SCHEDULE:
Visit log Date of visit Gestationalweek
Plasma 
glucose
Acarbose 
dose
J. USG FINDINGS:
22 weeks 28 weeks 32 weeks 36 weeks
K. OUTCOME OF PRESENT PREGNANCY:
Delivered-yes/no
If no,was it wasted:
If delivered:
 Date of delivery:
 Sex of baby:
 Mode of delivery:spontaneous( ) Induction( ) Caesarean( )
 Weight:
 Height:
 Apgar :
 New born infants blood glucose:
L. MATERNAL COMPLICATIONS:
Proteinuria:
Retinopathy:
Pre-eclampsia:
PCOD:
Others:
M. NEONATAL COMPLICATIONS:
 Congenital abnormality (if yes, specify):
Neonatal hypoglycemia:
Shoulder dystocia:
Other information:
ABBREVIATIONS
IQ - Intelligence Quotient
RDS - Respiratory Distress Syndrome
USA - United States of America
GDM - Gestational Diabetes Mellitus
DM - Diabetes Mellitus
WHO - World Health Organisation
BD - Bi Diurnal
HbA1c - Heamoglobin A1c
BMI - Body Mass Index
LSCS - Lower Segment Caesarean Section
PROM - Premature Rupture Of Membranes
CPD - Cephalo Pelvic Disproportion
PIH - Pregnancy Induced Hypertension
PCOS - Poly Cystic Ovarian Syndrome
IGT - Impaired Glucose Tolerance
IUD - Intra Uterine Death
USG - Ultrasonogram
LMP - Last Menstrual Period
EDD - Expected Date Of Delivery
KEY TO MASTER CHART
Obstetrics History:
Gravida 1 - 1
Gravida 2 - 2
Gravida 3 - 3
Family History:
Present  -  +
Absent  -  −
Delivery Mode:
Labour Natural - 1
Caesarian Section - 2
Maternal complications:
PIH - 1
PCOD - 2
IGT - 3
Fetal Wastage:
One abortion - 1
Two abortion - 2
Three abortion - 3
Glycemic control:
Good - G
Fair - F
Poor - P
Ultrasound :
Normal - N
Hydramnios - Hyd
Oligohydramnios - Oligo
Macrosomia - Macro
Renal Anomaly - Renal An.
Live Baby:
Live Baby - 1
Dead Born - 2
Sex :
Male - M
Female - F
Apgar score: 
More than 7 at 10 minutes - G
Less than 7 at 10 minutes - F
Less than 5 at 10 minutes - P
